Ad Header



The Pulse of the Pharmaceutical Industry

Novartis wins FDA’s breakthrough tag for lung cancer hopeful

Written by: | | Dated: Friday, September 6th, 2019


ZURICH (Reuters) – Novartis has secured the U.S. Food and Drug Administration’s Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.


Reporting by John Miller; Editing by Michael Shields and David Goodman


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom